ReviewSynthetic biology (Oxford, England)2021
Development of synthetic biotics as treatment for human diseases.
Review in Synthetic biology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Metabolic shifts driven by host-microbial interactions.The FEBS journal · 2026Review
- Synthetic biology and genome engineering in support of human, agricultural, and environmental security.Frontiers in bioengineering and biotechnology · 2026Article
- Genetic Entanglement Enables Ultrastable Biocontainment in the Mammalian Gut.ACS synthetic biology · 2025Article
- Construction of a genome-engineered stable 5-aminolevulinic acid producingSynthetic and systems biotechnology · 2025Article
- Systematic Engineering for Efficient Uric Acid-Degrading Activity in Probiotic YeastACS synthetic biology · 2025Article
- Live Biotherapeutic Products for Metabolic Diseases: Development Strategies, Challenges, and Future Directions.Journal of microbiology and biotechnology · 2025Review
- Reshaping the Treatment Landscape of a Galactose Metabolism Disorder.Journal of inherited metabolic disease · 2025Review
- Intein-based thermoregulated meganucleases for containment of genetic material.Nucleic acids research · 2024Article
- Gut-on-a-Chip Research for Drug Development: Implications of Chip Design on Preclinical Oral Bioavailability or Intestinal Disease Studies.Biomimetics (Basel, Switzerland) · 2023Review
- Fighting fire with fire: engineering a microbe into a therapeutic defense against drug-resistant biofilms.Synthetic biology (Oxford, England) · 2023Article
- Targeted Antimicrobial Agents as Potential Tools for Modulating the Gut Microbiome.Frontiers in microbiology · 2022Review
- Achieving spatially precise diagnosis and therapy in the mammalian gut using synthetic microbial gene circuits.Frontiers in bioengineering and biotechnology · 2022Review
- Microbiome engineering: engineered live biotherapeutic products for treating human disease.Frontiers in bioengineering and biotechnology · 2022Review
- From DNA-protein interactions to the genetic circuit design using CRISPR-dCas systems.Frontiers in molecular biosciences · 2022Review
- Gut microbiome therapy: fecal microbiota transplantation vs live biotherapeutic products.Gut microbesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in synthetic biology have allowed the generation of strains of bacteria that are genetically altered to have specific therapeutic benefits. These synthetic biotics, also widely referred to as engineered living therapeutics, have tremendous potential as a new therapeutic modality, and several have advanced into the clinic and human testing. This review outlines some of the unique attributes of synthetic biotics as well as some of the challenges in their development as prescription products. Regulatory considerations are discussed, and a case study of a program that has advanced into Phase 2 testing is provided: SYNB1618 for the treatment of PKU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.